Gliclazide Dosing in Severe Renal Impairment

Introduction to Gliclazide Alternatives

• The American Diabetes Association and Kidney Disease: Improving Global Outcomes recommend SGLT2 inhibitors for patients with type 2 diabetes and eGFR ≥20, although the glycemic effect is blunted at eGFR 19 2
• The Endocrine Society suggests considering alternative agents such as glimepiride (starting at 1 mg daily) or repaglinide (starting at 0.5 mg with meals) for patients with eGFR 19, as gliclazide is not listed in major guidelines for dosing recommendations in advanced chronic kidney disease 1

Dosing Recommendations for Alternative Agents

• The Endocrine Society recommends starting glimepiride at 1 mg daily with careful monitoring for patients with eGFR 19, as it is hepatically metabolized, reducing accumulation risk 1
• The American College of Clinical Endocrinologists suggests starting repaglinide conservatively at 0.5 mg with meals for eGFR <30, as it is hepatically metabolized and has a shorter duration of action, which may reduce hypoglycemia risk 1

Critical Safety Considerations

• The Kidney Disease: Improving Global Outcomes guideline highlights that hypoglycemia risk is substantially elevated in patients with eGFR <30 due to reduced renal clearance of insulin and some oral agents, decreased renal gluconeogenesis, impaired counter-regulatory responses, and reduced clearance of active metabolites 2

Modern Guideline-Directed Therapy

• The American Diabetes Association and Kidney Disease: Improving Global Outcomes recommend GLP-1 receptor agonists with proven cardiovascular benefit and DPP-4 inhibitors with renal dose adjustment (such as alogliptin 6.25 mg daily for eGFR <30) as safer alternatives to sulfonylureas, with superior cardiovascular and renal outcomes 2
• The Endocrine Society suggests that DPP-4 inhibitors, such as alogliptin, can be used as an alternative to gliclazide, with a recommended dose of 6.25 mg daily for eGFR <30 1